Synageva BioPharma to Present at the 30th Annual J.P. Morgan Healthcare Conference on January 11, 2012
LEXINGTON, Mass.--(BUSINESS WIRE)-- Synageva BioPharma Corp. , (Synageva) (NASDAQ:GEVA) a clinical stage biopharmaceutical company developing therapeutic products for rare disorders announced today that it will be presenting at the upcoming 30th Annual J.P. Morgan Healthcare Conference, which is being held January 9-12, 2012, at the Westin St. Francis Hotel in San Francisco.
Sanj K. Patel, President and Chief Executive Officer of Synageva, is scheduled to present on Wednesday, January 11, 2012, at 11:00 AM Pacific Standard Time/2:00 PM Eastern Standard Time. The presentation will be available via webcast at http://jpmorgan.metameetings.com/webcasts/healthcare12/directlink?ticker=GEVA. A replay link will also be available following the live presentation on the company's website at http://www.synageva.com.
About Synageva BioPharma Corp. (GEVA)
Synageva is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Synageva has several protein therapeutics in its pipeline. The company has assembled a team with a proven record of bringing orphan therapies to patients.
About Synagevas Lead Program
SBC-102 is being developed as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD), and is a recombinant form of the human LAL enzyme. SBC-102 is currently being evaluated in global Phase I/II clinical trials, has been granted orphan designations by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency, and fast track designation by the FDA.
Further information regarding Synageva BioPharma Corp. is available at http://www.synageva.com.
Matthew Osborne, 781-357-9900
Source: Synageva BioPharmaCopyright Business Wire 2011